KR101284361B1 - 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 - Google Patents

4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 Download PDF

Info

Publication number
KR101284361B1
KR101284361B1 KR1020077006837A KR20077006837A KR101284361B1 KR 101284361 B1 KR101284361 B1 KR 101284361B1 KR 1020077006837 A KR1020077006837 A KR 1020077006837A KR 20077006837 A KR20077006837 A KR 20077006837A KR 101284361 B1 KR101284361 B1 KR 101284361B1
Authority
KR
South Korea
Prior art keywords
formula
compound
pharmaceutical composition
tablet
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077006837A
Other languages
English (en)
Korean (ko)
Other versions
KR20070074555A (ko
Inventor
파울 테오도르 아그네스 스티븐스
조제프 피터스
로거 페트루스 그레베른 반데크루이스
알프레드 엘리자벳 스텝퍼스
알렉스 헤르만 쿠프만스
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38091637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101284361(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Priority claimed from PCT/EP2005/054342 external-priority patent/WO2006024668A1/en
Publication of KR20070074555A publication Critical patent/KR20070074555A/ko
Application granted granted Critical
Publication of KR101284361B1 publication Critical patent/KR101284361B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hybrid Cells (AREA)
KR1020077006837A 2004-09-02 2005-09-02 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 Expired - Lifetime KR101284361B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
MYPI20043578 2004-09-02
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EPPCT/EP2004/052028 2004-09-03
EP05101467.8 2005-02-25
EP05101467 2005-02-25
PCT/EP2005/054342 WO2006024668A1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile

Publications (2)

Publication Number Publication Date
KR20070074555A KR20070074555A (ko) 2007-07-12
KR101284361B1 true KR101284361B1 (ko) 2013-07-15

Family

ID=38091637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077006837A Expired - Lifetime KR101284361B1 (ko) 2004-09-02 2005-09-02 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드

Country Status (23)

Country Link
EP (1) EP1632232B3 (https=)
JP (1) JP4912309B2 (https=)
KR (1) KR101284361B1 (https=)
CN (1) CN104586850A (https=)
AT (1) ATE508748T1 (https=)
BR (1) BRPI0514871A (https=)
CY (3) CY1112249T1 (https=)
DK (1) DK1632232T6 (https=)
EA (1) EA013686B1 (https=)
ES (1) ES2371442T7 (https=)
FR (2) FR16C1023I2 (https=)
HK (1) HK1210029A1 (https=)
HU (2) HUS1600061I1 (https=)
IL (1) IL181650A (https=)
LT (2) LTC1632232I2 (https=)
ME (1) ME01246B (https=)
MX (1) MX2007002595A (https=)
NI (1) NI200700068A (https=)
NO (3) NO340654B1 (https=)
PL (1) PL1632232T6 (https=)
PT (1) PT1632232E (https=)
RS (1) RS51923B2 (https=)
SI (1) SI1632232T1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PT1981506E (pt) * 2006-01-20 2013-06-25 Janssen R & D Ireland Tratamento a longo prazo da infeção pelo vih com tmc278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
KR101879468B1 (ko) * 2011-04-15 2018-07-17 엠큐어 파마슈티컬즈 리미티드 릴피비린 중간체의 제조를 위한 공정
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
GR1008965B (el) * 2015-12-02 2017-02-28 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
US11065198B2 (en) * 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040023645A (ko) * 2001-08-13 2004-03-18 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307543B1 (en) * 1998-09-10 2001-10-23 Silicon Image, Inc. Bi-directional data transfer using two pair of differential lines as a single additional differential pair
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DK1529032T3 (da) * 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0407329A (pt) * 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040023645A (ko) * 2001-08-13 2004-03-18 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체

Also Published As

Publication number Publication date
FR16C1023I1 (fr) 2017-02-03
PT1632232E (pt) 2011-08-02
CY2016050I1 (el) 2017-07-12
FR16C1025I1 (fr) 2017-02-03
CY2016051I1 (el) 2017-07-12
NO2017065I1 (no) 2017-11-21
NO20071745L (no) 2007-04-02
EP1632232B1 (en) 2011-05-11
DK1632232T3 (da) 2011-08-22
CY1112249T1 (el) 2015-12-09
EA013686B1 (ru) 2010-06-30
RS51923B (sr) 2012-02-29
DK1632232T6 (da) 2022-04-19
HUS1600061I1 (hu) 2017-01-30
MX2007002595A (es) 2007-04-25
ES2371442T3 (es) 2012-01-02
NI200700068A (es) 2016-09-29
BRPI0514871A (pt) 2008-06-24
KR20070074555A (ko) 2007-07-12
CN104586850A (zh) 2015-05-06
NO2017063I1 (no) 2017-11-21
NO340654B1 (no) 2017-05-22
LTC1632232I2 (lt) 2024-09-10
PL1632232T6 (pl) 2022-06-27
FR16C1023I2 (fr) 2025-11-21
EP1632232A1 (en) 2006-03-08
ME01246B (me) 2013-06-20
HUS1600060I1 (hu) 2017-01-30
LTPA2016042I1 (lt) 2017-01-10
EA200700536A1 (ru) 2007-08-31
JP4912309B2 (ja) 2012-04-11
ES2371442T7 (es) 2022-05-12
FR16C1025I2 (fr) 2025-11-21
RS51923B2 (sr) 2022-05-31
JP2008511592A (ja) 2008-04-17
HK1210029A1 (en) 2016-04-15
LTPA2016043I1 (lt) 2017-01-10
PL1632232T3 (pl) 2011-10-31
ATE508748T1 (de) 2011-05-15
SI1632232T1 (sl) 2011-09-30
EP1632232B3 (en) 2022-03-30
IL181650A (en) 2012-08-30
IL181650A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
US7956063B2 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
HK1210029A1 (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile
AU2005279158C1 (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
KR102861006B1 (ko) 분산성 조성물
US8101629B2 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20180116964A1 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
WO2006024667A1 (en) Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
NZ553323A (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, also named TMC278
NZ553322A (en) Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also named TMC278
HK1112862B (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

FPAY Annual fee payment

Payment date: 20180615

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190530

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20200618

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20210617

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20220615

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250903

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION